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SLEDAIAbstract Aim of the work: To study the relation of the immune profile to dyslipidemia in a cohort
of Egyptian Systemic Lupus Erythematosus (SLE) patients.
Patients and methods: This study included 221 SLE patients with a disease duration >6 months
at study entry. Disease activity was assessed using the SLE Disease Activity Index (SLEDAI) and
severity using the Systemic Lupus International Collaborating Clinics/Damage Index (SLICC/DI).
Patients were investigated for the anti-nuclear antibody (ANA), anti-double stranded deoxy-
ribonucleic acid (anti-dsDNA), anti-cardiolipin (ACL) antibodies (IgG and IgM), anti Ro (SSA)
and anti La (SSB). Dyslipidemia was considered if the high density lipoproteins (HDL), low density
lipoproteins (LDL), total cholesterol (TC) or triglycerides (TG) were abnormal.
Results: The mean age of the patients was 28.8 ± 7.8 years and the median disease duration was
5 years. The clinical manifestations of the patients were pleurisy (52.9%), pericarditis (24.9%),
nephritis (68.3%), CNS lupus (23.1%), vasculitis (14.9%) and musculoskeletal manifestations
(57.9%). All patients were on corticosteroids (median dose 35 mg/day; range 5–80 mg/day), while
92 (43.4%) of them received cyclophosphamide during their disease course. The mean SLEDAI
was 12.1 ± 7.4 and SLICC/DI was 1.4 ± 1.6. Patients with positive anti-Ro (n= 44; 19.9%)
showed statistically significant lower level of HDL (p= 0.01).
Conclusion: Positive anti-Ro may be associated with increased incidence of low HDL in lupus
patients which in turn may increase the incidence of cardiovascular accidents.
 2016 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
It is proved that Dyslipidemias are being increasingly recog-
nized as an important cause of development of cardiovascular
disease (CVD) [1]. An increase of 1% in total cholesterol
causes 2% increase in the incidence of ischemic heart diseasen Rheu-
Table 1 Laboratory data of the Systemic Lupus Erythemato-
sus patients.
Parameter n (%) or median (range) SLE patients (n= 221)
Immune profile
Positive test Anti-ANA 212 (95.9)
Anti-ds DNA 150 (67.9)
ACL 71 (32.1)
Anti Ro 44 (19.9)
Anti La 14 (6.3)
Lipid profile (mg/dL)
High TG 79 (35.7)
High cholesterol 113 (51.1)
High LDL 67 (30.3)
Risk (low) HDL 99 (44.8)
Hb (mg/dL) 10.5 (4.5–15.9)
TLC (103) 6.9 (1.4–26.3)
PLT (103) 272 (11–690)
ESR (mm/1st h) 61.0 (5–150)
ALT (IU/L) 21.0 (6–508)
Creatinine (mg/dL) 0.75 (0.2–6.2)
Proteinuria (mg/24 h) 0.83 (0–5.9)
C3 (mg/dL) 80 (98–178)
C4 (mg/dL) 15 (1–130)
SLE: Systemic Lupus Erythematosus, ANA: antinuclear antibod-
ies, dsDNA: double stranded deoxy-ribonucleic acid, ACL: anti-
cardiolipin, Hb hemoglobin, TLC: total leukocytic count, ESR:
erythrocyte sedimentation rate, ALT: alanine transaminase, C:
complement.
2 S.M. Gamal et al.(IHD) [2]. In fact atherosclerotic cardiovascular diseases
(ASCVD) are also the leading cause of morbidity and mortal-
ity in various autoimmune diseases, mainly rheumatoid arthri-
tis, antiphospholipid syndrome (APS) and Systemic Lupus
Erythematosus (SLE) [3,4]. SLE is a complex autoimmune dis-
ease characterized by immune disturbances and involvement of
multiple systems and organs. Dyslipidemia in Egyptian SLE
patients was reported to be associated with decreased quality
of life and damage accrual with an increased risk of atheroscle-
rosis [5].
Although the survival of SLE patients has improved during
the past three decades; however, they still die at a rate that is
three times higher than that of the general population [6] while
early deaths could be explained by active disease and infection,
late deaths (patients aged >40 years) are mainly attributed to
CVD [7,8]. Recent advances in the etiology of accelerated
atherosclerosis in SLE have stressed the relevance of the inter-
play between lupus-specific inflammatory factors and tradi-
tional cardiac risk factors in causing increased endothelial
damage [9].
The presence of autoantibodies is a cardinal feature of SLE
[10]. Quantification on the serum levels and/or prevalence of
one or more autoantibodies recently demonstrated their signif-
icance in the disease pathology [11]. Anti-double stranded
deoxy-ribonucleic acid (anti-dsDNA) antibodies were signifi-
cantly associated with lupus nephritis (LN) [12,13] and both
anti-Ro and anti-La antibodies were strongly associated with
skin manifestations [14] in SLE patients.
Thus the aim of the current study was to investigate the
relation of SLE associated autoantibodies and dyslipidemia
in a cohort of Egyptian patients.Please cite this article in press as: Gamal SM et al. Immunological profile and dyslipid
matologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.05.0072. Patients and methods
The study, descriptive and cross-sectional, included 221 Egyp-
tian SLE patients fulfilling the updated ACR revised criteria
for the classification of SLE [15]. All the patients had the dis-
ease duration more than 6 months at study entry. The patients
were attending the Rheumatology department of Cairo
University Hospitals during 2014.
All Patients were subjected to full history taking, thorough
clinical examination, laboratory and relevant radiological
investigations were performed for all the patients. Disease
activity was assessed using the SLE Disease Activity Index
(SLEDAI) [16] and severity using the Systemic Lupus Interna-
tional Collaborating Clinics/Damage Index (SLICC/DI) [17].
The clinical manifestations are described based on the SLE-
DAI and SLICC items. The study has been approved by local
ethics committee and it conforms to the standards currently
applied in Cairo University Teaching Hospitals. Patients gave
an informed consent before being enrolled in the study.
The information collected included the history of smoking,
alcohol intake, presence of diabetes mellitus, and dose of ster-
oid. A detailed dietary history was also included.
For all patients, serological examinations were performed
including the following: (A) Immune profile: Anti-nuclear anti-
body and anti-ds DNA tests were carried out by indirect
Immunofluorescence (IIF) technique; anti-cardiolipin antibod-
ies (ACL) (IgG and IgM) and anti-Ro (SSA) and Anti-La
(SSB) were detected by ELISA. (B) Lipid profile: high density
lipoproteins (HDL), low density lipoproteins (LDL), total
cholesterol (TC) and triglycerides (TG) were checked. A diag-
nosis of dyslipidemia was given if the patient had (a) hyperc-
holesterolemia, defined as taking lipid-lowering medication as
a surrogate, or having a fasting plasma TCP 200 mg/dL (b)
HDL 6 40 mg/dL, (c) hypertriglyceridemia (TGP 150 mg/
dL) or (d) elevated LDL (P100 mg/dL) [18].
Statistical analysis: Data were statistically described in
terms of range, mean ± standard deviation (SD), median, fre-
quencies (number of cases) and percentages when appropriate.
Comparison of quantitative variables between the study
groups was done using Mann–Whitney U-test for independent
samples. For comparing categorical data, Chi-square (v2) test
was performed. Exact test was used instead when the expected
frequency is less than 5. A probability value (p value) less than
0.05 was considered statistically significant. All statistical cal-
culations were done using computer programs Microsoft Excel
2003 (Microsoft Corporation, NY, USA) and SPSS (Statistical
Package for the Social Science; SPSS Inc., Chicago, IL, USA)
version 15 for Microsoft Windows.
3. Results
This study included 221 SLE patients, 212 (95.9%) females
and 9 males (4.1%). Their ages ranged from 17 to 54 years
with a mean of 28.8 ± 7.8 years. Their disease duration ranged
from 0.5 to 20 years with a median of 5 years. The main clin-
ical presentation of our patients included pleurisy (52.9%),
pericarditis (24.9%), nephritis (68.3%), CNS lupus (23.1%),
vasculitis (14.9%), and musculoskeletal manifestations
(57.9%). None of our patients had history of smoking, alcohol
intake or presence of diabetes mellitus. All of our patients were
on corticosteroids, their doses ranged from 5 to 80 mg/dayemia in Egyptian Systemic Lupus Erythematosus patients, The Egyptian Rheu-
Table 2 Comparison between lipid profile in those with positive vs negative auto-antibodies (ANA, anti-ds DNA and ACL) in SLE
patients.
Parameter n (%) Systemic Lupus Erythematosus patients (n= 221)
ANA Anti-ds DNA ACL
ve +ve p ve +ve p ve +ve p
TG
Normal 7 (4.9) 135 (95.1) 0.38 48 (33.8) 94 (66.2) 0.47 99 (69.7) 43 (30.3) 0.43
High 2 (2.5) 77 (97.5) 23 (29.1) 56 (70.9) 51 (64.6) 28 (35.4)
Chol.
Normal 5 (4.6) 103 (95.4) 0.68 39 (36.1) 69 (63.9) 0.21 70 (64.8) 38 (35.2) 0.34
High 4 (3.5) 109 (96.5) 32 (28.3) 81 (71.7) 80 (70.8) 33 (29.2)
LDL
Normal 5 (3.2) 149 (96.8) 0.34 48 (31.2) 106 (68.8) 0.64 105 (68.2) 49 (31.8) 0.88
High 4 (6) 63 (94) 23 (34.3) 44 (65.7) 45 (67.2) 22 (32.8)
HDL
Risk 3 (3) 96 (97) 0.48 29 (29.3) 70 (70.7) 0.41 65 (65.7) 34 (34.3) 0.56
Normal 6 (4.9) 116 (95.1) 42 (34.4) 80 (65.6) 85 (69.7) 37 (30.3)
ANA: antinuclear antibodies, dsDNA: double stranded deoxy-ribonucleic acid, ACL: anticardiolipin, TG: triglycerides, Chol: cholesterol,
LDL: low density lipoprotein, HDL: high density lipoprotein.
Table 3 Comparison between lipid profile in those with positive vs negative anti-Ro and anti-La in SLE patients.
Parameter n (%) Systemic Lupus Erythematosus patients (n= 221)
Anti-Ro Anti-La
ve +ve p ve +ve p
TG
Normal 114 (80.3) 28 (19.7) 0.92 132 (93) 10 (7) 0.56
High 63 (79.7) 16 (20.3) 75 (94.9) 4 (5.1)
Chol.
Normal 91 (84.3) 17 (15.7) 0.13 99 (91.7) 9 (8.3) 0.23
High 86 (76.1) 27 (23.9) 108 (95.6) 5 (4.4)
LDL
Normal 122 (79.2) 32 (20.8) 0.62 143 (92.9) 11 (7.1) 0.46
High 55 (82.1) 12 (17.9) 64 (95.5) 3 (4.5)
HDL
Risk 72 (72.7) 27 (27.3) 0.01 92 (92.9) 7 (7.1) 0.69
Normal 105 (86.1) 17 (13.9) 115 (94.3) 7 (5.7)
TG: triglycerides, Chol: cholesterol, LDL: low density lipoprotein, HDL: high density lipoprotein.
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Cyclophosphamide during their disease course. Laboratory
data of the SLE patients are shown in Table 1.
The level of SLEDAI ranged between 0 and 34 (mean: 12.1
± 7.4) and that of the SLICC was between 0 and 8 (mean: 1.4
± 1.6), however no statistically significant difference was
found regarding both indices and any of lipid profile variables.
On comparing those with positive and negative immune
profile as regards the abnormalities in triglyceride, cholesterol,
LDL and HDL, patients with positive anti-Ro were found to
have significantly lower HDL (p= 0.01); otherwise no signif-
icant statistical difference was found as shown in Tables 2
and 3.Please cite this article in press as: Gamal SM et al. Immunological profile and dyslipid
matologist (2016), http://dx.doi.org/10.1016/j.ejr.2016.05.0074. Discussion
Systemic LupusErythematosus is the classic of systemic autoim-
mune diseases characterized by the production of a broad spec-
trum of autoantibodies [19]. Lupus autoantibodies are
correlated with the occurrence of specific clinical symptoms
and patients with a negative autoantibody profile had fewer
clinical and laboratory features of their disease compared to
those with a positive profile [20]. Antinuclear antibodies, such
as anti-ds DNA, antiribosomal P, anti-Sm, anti-ribonu-
cleoprotein (anti-RNP) and even anti-Sjo¨gren’s syndrome
(SS)-B/La antibodies not only act against specific nuclear
antigens but also cross-react with different surface-expressedemia in Egyptian Systemic Lupus Erythematosus patients, The Egyptian Rheu-
4 S.M. Gamal et al.cognatemolecules. The binding of autoantibodies to the cell sur-
face leads to their penetration into the cell’s interior to elicit cel-
lular damage [19].
It is now well established that cerebrovascular events,
myocardial infarction and subclinical atherosclerosis are
increasingly recognized as serious complications of SLE [21].
Dyslipidemia is a significant comorbidity of lupus patients
with multiple negative effects on the long term [22].
It is well recognized that dyslipidemia with low HDL raised
TGs, unchanged or only slightly elevated LDL; is typical of
SLE, especially in active disease, and this lipid pattern has been
described as the ‘‘lupus pattern of dyslipoproteinemia,” but the
underlying mechanisms are not well known [23]. There is mul-
tifactorial origin of the dyslipidemia existing in SLE patients.
So the aim of the present study was to investigate if there is
any relation between SLE associated autoantibodies and the
abnormal lipid profile in Egyptian SLE patients.
Our findings were consistent with the findings of Toms and
coworker [24] and Khairy and her colleagues [25] as they
reported that increased frequency of dyslipidemia with raised
triglycerides decreased HDL-cholesterol concentration could
be seen frequently in SLE patients.
Positive Anti Ro antibodies increases the risk of developing
lupus nephritis [26], thus the association of low HDL in our
study with positive anti-Ro antibodies could simply be
explained when we know that nephritis and 24 h urinary pro-
tein are commonly associated with premature atherosclerosis
in lupus patients [9].
In conclusion, Positive anti-Ro may be associated with low
level of HDL which in turn is associated with an increased risk
of cardiovascular accidents in lupus patients, however further
studies including a higher number of patients with multivariate
analysis may be required to establish such results.Conflict of interest
None.
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